Publications
Where expertise meets impact
Berry doesn’t just follow industry standards — we set them. Our team of award-winning statisticians, journal editors, and regulatory advisors leads the field in Bayesian and adaptive trial design. With research published in The New England Journal of Medicine, JAMA, and The Lancet, we’re driving innovation where it matters most.
Over 90% of our scientists published influential work this past year, advancing adaptive, Bayesian, and platform trial methodology. Our blend of academic rigor, regulatory insight, and real-world experience makes Berry a true authority in modern clinical trials.
Explore our most impactful peer-reviewed publications below.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Alzheimer's Association
Rare Diseases
The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model
August 29, 2016
2016
DOI: 10.1016/j.jalz.2016.07.005
The New England Journal of Medicine
Oncology
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
July 7, 2016
2016
doi: 10.1056/NEJMoa1513749
The New England Journal of Medicine
Oncology
Adaptive Randomization of Neratinib in Early Breast Cancer
July 7, 2016
2016
DOI: 10.1056/NEJMoa1513750
Alzheimer's Association
Neuroscience
Alzheimer's Disease
Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease
February 4, 2016
2016
DOI: 10.1016/j.trci.2016.01.001
Sage Journals
Rare Diseases
A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response
January 14, 2016
2016
DOI: 10.1177/1740774515621721
American Heart Association Journal
Neuroscience
Stroke
Adopting a Patient-Centered Approach to Primary Outcome Analysis of Acute Stroke Trials Using a Utility-Weighted Modified Rankin Scale
July 2, 2015
2015
DOI: 10.1161/STROKEAHA.114.008547
Clinical Pharmacology & Therapeutics (CPT)
Oncology
The Signature Program: Bringing the Protocol to the Patient
March 25, 2015
2015
DOI: 10.1002/cpt.126
Society of Critical Care Medicine
Sepsis
An Adaptive, Phase II, Dose-Finding Clinical Trial Design to Evaluate l-Carnitine in the Treatment of Septic Shock Based on Efficacy and Predictive Probability of Subsequent Phase III Success
February 19, 2015
2015
doi: 10.1097/CCM.0b013e318287f850
No results found.
There are no results with this criteria. Try changing your search.